Overview of Phase 3 clinical trial UKALL14 for ALL

David Marks, MD, PhD, from the University Hospitals Bristol NHS Foundation Trust, Bristol, UK, provides an overview of the randomized Phase 3 clinical trial UKALL14 for adult acute lymphocytic leukemia (ALL). Two of the main questions the trial seeks to answer is whether rituximab improves survival of B-cell ALL and whether nelarabine improves survival of T-cell ALL. Dr Marks also talks about how the field is changing in regard to relapsed/refractory ALL.
Recorded at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.